Pro-resolving lipid mediators in the resolution of neointimal hyperplasia pathogenesis in atherosclerotic diseases.
Atherosclerosis
inflammation
lipoxins
neointimal hyperplasia
pro-resolving mediators
protectins
resolvins
Journal
Expert review of cardiovascular therapy
ISSN: 1744-8344
Titre abrégé: Expert Rev Cardiovasc Ther
Pays: England
ID NLM: 101182328
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
pubmed:
26
12
2018
medline:
4
4
2019
entrez:
25
12
2018
Statut:
ppublish
Résumé
Despite advances in drug eluting technologies, neointimal hyperplasia (NIH) and restenosis still plagues endovascular therapy in atherosclerotic diseases. By appreciating atherosclerosis and NIH as complex inflammatory processes, specialized pro-resolving mediators (SPMs) are a superfamily of endogenous unsaturated fatty-acid derived lipids with the potential for inflammatory resolution. Areas covered: Inquiry into SPMs in this context is a novel approach and is the focus of this review, with emphasis on our understanding with NIH. Prior mechanistic understandings of SPM deficiency with atherosclerosis has offered insight, as well as the complexity and diversity of the SPM superfamily. Therapeutic investigation using SPMs to combat NIH is also evaluated here. Expert commentary: Endogenous deficiency of SPMs synthesis by 12/15-lipoxygenase underlies resolution deficits in atherosclerosis and NIH. Upstream PDGF inhibition by SPMs, most notably RvD1 and LXA4, confers a multifactorial attenuation of NIH that involves interconnected anti-inflammatory efforts, most notably switch pro-resolving smooth muscle cells (vSMCs) and macrophages. The ALX/FPR2 is one receptor system identified on vSMCs that interacts with these SPMs to promote NIH resolution. Therapeutically, while shown to be promising with less stent burden or cytotoxicity, SPMs must be balanced by necessary mechanistic, pharmacokinetic and anatomical considerations.
Identifiants
pubmed: 30582389
doi: 10.1080/14779072.2019.1563483
pmc: PMC6679914
mid: NIHMS1535416
doi:
Substances chimiques
Inflammation Mediators
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
177-184Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL147662
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL116042
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL144125
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL120659
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL128063
Pays : United States
Références
Nature. 2014 Jun 5;510(7503):92-101
pubmed: 24899309
Am J Pathol. 2010 Oct;177(4):2116-23
pubmed: 20709806
Sci Rep. 2018 Mar 2;8(1):3940
pubmed: 29500419
J Immunol. 2003 Dec 15;171(12):6856-65
pubmed: 14662892
Cardiovasc Res. 2004 Mar 1;61(4):671-82
pubmed: 14985064
Cardiovasc Res. 1996 Jun;31(6):835-46
pubmed: 8759238
Br Med Bull. 2013;106:193-211
pubmed: 23532779
Circ Res. 2016 Jun 24;119(1):113-30
pubmed: 27340271
Atherosclerosis. 2008 May;198(1):136-44
pubmed: 17959182
Arterioscler Thromb Vasc Biol. 2003 Sep 1;23(9):1510-20
pubmed: 12907463
Proc Natl Acad Sci U S A. 2016 Jun 7;113(23):6526-31
pubmed: 27199481
Cardiovasc Res. 2010 May 1;86(2):243-53
pubmed: 20093252
Atherosclerosis. 1999 Jul;145(1):33-43
pubmed: 10428293
BMC Med. 2013 May 01;11:117
pubmed: 23635324
Ann N Y Acad Sci. 1997 Apr 15;811:459-70
pubmed: 9186623
Atherosclerosis. 2012 Nov;225(1):121-7
pubmed: 22980500
Immunity. 2014 Mar 20;40(3):315-27
pubmed: 24656045
FASEB J. 2008 Oct;22(10):3595-606
pubmed: 18559988
J Surg Res. 2019 Jan;233:104-110
pubmed: 30502235
J Am Coll Cardiol. 2003 Feb 19;41(4 Suppl S):15S-22S
pubmed: 12644336
J Interv Cardiol. 2010 Aug;23(4):411-9
pubmed: 20806458
Arterioscler Thromb Vasc Biol. 2005 Oct;25(10):2081-7
pubmed: 16123317
Circulation. 2002 Feb 5;105(5):633-8
pubmed: 11827931
Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12165-70
pubmed: 14530386
J Vasc Surg. 2007 Jun;45 Suppl A:A15-24
pubmed: 17544020
Prog Lipid Res. 2011 Jan;50(1):115-31
pubmed: 20970452
FASEB J. 2017 Aug;31(8):3393-3402
pubmed: 28442547
FASEB J. 2018 Oct;32(10):5413-5425
pubmed: 29723062
Circulation. 1992 Jul;86(1):56-63
pubmed: 1617790
Prostaglandins Leukot Essent Fatty Acids. 2005 Sep-Oct;73(3-4):163-77
pubmed: 16125378
N Engl J Med. 2016 Mar 17;374(11):1021-31
pubmed: 26890472
Eur Heart J. 2016 Dec 01;37(45):3386-3395
pubmed: 27578808
Circ Res. 2016 Oct 14;119(9):1030-1038
pubmed: 27531933
Expert Rev Cardiovasc Ther. 2012 May;10(5):635-47
pubmed: 22651839
Catheter Cardiovasc Interv. 2000 Jun;50(2):160-7
pubmed: 10842380
Arterioscler Thromb Vasc Biol. 2007 Jan;27(1):15-26
pubmed: 17082488
Nat Commun. 2016 Sep 23;7:12859
pubmed: 27659679
FASEB J. 2015 Jun;29(6):2504-13
pubmed: 25777995
J Immunol. 2017 Jan 15;198(2):842-851
pubmed: 27994074
Eur J Clin Invest. 2010 Jan;40(1):11-7
pubmed: 19912316
FASEB J. 2013 Jun;27(6):2220-32
pubmed: 23407709
Br J Pharmacol. 2017 Nov;174(22):4043-4054
pubmed: 28071789
J Biol Chem. 2001 Sep 14;276(37):35071-7
pubmed: 11451962
Proc Natl Acad Sci U S A. 2014 Oct 7;111(40):14530-5
pubmed: 25246560
Eur J Vasc Endovasc Surg. 2004 Aug;28(2):132-7
pubmed: 15234692
J Vasc Surg. 2017 Jan;65(1):207-217.e3
pubmed: 27034112
J Am Coll Cardiol. 2000 Mar 1;35(3):555-62
pubmed: 10716455
Cardiovasc J Afr. 2015 Jan-Feb;26(1):34-7
pubmed: 25784315
Adv Pharmacol. 2018;81:241-330
pubmed: 29310800
FASEB J. 2016 Aug;30(8):2792-801
pubmed: 27121596
Prog Lipid Res. 2006 Jul;45(4):334-56
pubmed: 16678271
Int J Cardiol. 2015 Jan 20;179:370-2
pubmed: 25464488
J Biol Chem. 2014 Mar 21;289(12):8562-9
pubmed: 24497644
J Biol Chem. 2009 Jul 31;284(31):21077-89
pubmed: 19509298
Nature. 1993 Apr 29;362(6423):801-9
pubmed: 8479518
Circ Res. 2016 Oct 14;119(9):972-974
pubmed: 27737938
Circ Cardiovasc Interv. 2018 Jan;11(1):e005891
pubmed: 29326153